MedPath

Tagged News

RWJBarnabas Health and Rutgers Cancer Institute to Present 45 Groundbreaking Studies at ASCO 2025

OncologyPrecision MedicineMonoclonal Antibody
• Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.
• A notable multisite randomized trial demonstrated that problem-solving skills training significantly improved depression, anxiety, and quality of life in young adults newly diagnosed with cancer compared to standard care.
• New research revealed that patients living in both food and clinical trial deserts had 27% lower likelihood of breast cancer trial enrollment, highlighting how geographic and socioeconomic barriers impact cancer care access.

New-Onset Diabetes Emerges as Early Warning Signal for Pancreatic Cancer Detection

AIPrecision Medicine
  • New-onset diabetes (NOD) affects approximately 1% of pancreatic cancer cases and may serve as an early indicator of pancreatic ductal adenocarcinoma, with elderly NOD patients facing six to eight times higher cancer risk compared to the general population.
  • Research reveals that metabolic changes associated with pancreatic cancer-related diabetes begin occurring 1.5-2 years before cancer diagnosis, with notable increases in blood glucose and weight loss observed 6-18 months prior to clinical presentation.
  • Scientists have identified 75 proteins associated with pancreatic cancer-related diabetes and discovered potential biomarkers including specific miRNA profiles and elevated serum levels of galectin-3 and S100A9 that could distinguish cancer-associated diabetes from typical type 2 diabetes.
  • The ENDPAC risk prediction model and emerging AI-based screening strategies show promise for early detection, while comprehensive biobanking initiatives are being established to support biomarker discovery in ethnically diverse populations.

City of Hope to Present Groundbreaking Cancer Advances at 2025 ASCO Annual Meeting

Precision MedicineOncology
  • City of Hope researchers will showcase innovative cancer treatments at the 2025 ASCO Annual Meeting, including promising data on safely readministering trastuzumab-deruxtecan to breast cancer patients after lung complications.
  • A precision medicine study identified specific genomic biomarkers in kidney cancer patients that predict better outcomes with adjuvant atezolizumab, potentially enabling more personalized treatment approaches.
  • Novel combination therapy using checkpoint inhibitors Vilastobart and atezolizumab showed tumor shrinkage in colorectal cancer patients previously unresponsive to immunotherapy, representing a significant breakthrough.

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781Active, Not RecruitingPhase 3
National Cancer Institute (NCI)
Posted 9/8/2015

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/17/2020

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Active, Not RecruitingPhase 3
Gilead Sciences
Posted 7/25/2022

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT03793166Active, Not RecruitingPhase 3
National Cancer Institute (NCI)
Posted 6/7/2019

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Active, Not RecruitingPhase 3
Corcept Therapeutics
Posted 6/29/2022

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Active, Not RecruitingPhase 3
BeiGene
Posted 10/31/2017

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT04497844Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 9/23/2020

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

NCT04896697RecruitingPhase 1
Xilio Development, Inc.
Posted 9/13/2021

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

NCT03024996TerminatedPhase 3
Hoffmann-La Roche
Posted 1/3/2017

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT02998528CompletedPhase 3
Bristol-Myers Squibb
Posted 3/4/2017

MInimal Residual Disease Adapted Strategy

NCT04934475Active, Not RecruitingPhase 3
Intergroupe Francophone du Myelome
Posted 12/8/2021

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

NCT02828618Active, Not RecruitingNot Applicable
AGO Study Group
Posted 7/1/2016

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Active, Not RecruitingPhase 3
Regeneron Pharmaceuticals
Posted 6/4/2019

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536Active, Not RecruitingPhase 3
Celgene
Posted 1/2/2019

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 11/18/2021

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Active, Not RecruitingPhase 3
AstraZeneca
Posted 12/16/2020

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934Active, Not RecruitingPhase 3
AstraZeneca
Posted 6/30/2021

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Active, Not RecruitingPhase 3
Amgen
Posted 5/31/2023

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/16/2018

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Active, Not RecruitingPhase 3
Pfizer
Posted 12/21/2020

PacBio Partners with Haorui Gene to Expand Long-Read Sequencing Access Across China

Precision Medicine
  • PacBio has appointed Haorui Gene as an official distributor in China, expanding access to its HiFi long-read sequencing technology in clinical and research settings focused on transfusion medicine and hematology.
  • Haorui Gene, established in 2020, has rapidly become a leader in blood typing genomics with ten PacBio systems already deployed across China for HLA typing, blood group genotyping, and rare blood type discovery.
  • The partnership will distribute PacBio's Vega platform throughout China, supporting clinical laboratories and blood centers in building more complete blood group profiles with high-resolution genomic data.

FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials

Targeted TherapyOncologyPrecision Medicine
  • FORE Biotherapeutics has raised $38 million in Series D-2 financing to advance its global Phase 2 FORTE Master Protocol evaluating plixorafenib across multiple BRAF-mutated cancer indications.
  • The company anticipates interim analyses in 2025 across three monotherapy indications: BRAF V600 primary recurrent CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions.
  • Plixorafenib, designed with a first-in-class mechanism to address limitations of earlier BRAF inhibitors, has previously demonstrated promising efficacy with a 67% overall response rate in BRAF V600 primary recurrent CNS tumors.

Syantra Expands IP Portfolio with Novel "Tumor Education" Approach for Cancer Detection and Treatment

Precision MedicineOncology
  • Syantra has filed new patents expanding their cancer molecular diagnostics platform to include novel drug targets and therapeutics based on their "tumor education" approach.
  • The company's Onco-ID platform uses whole blood mRNA analysis to detect early-stage cancer by monitoring the body's immune response rather than cancer cells or DNA fragments.
  • Syantra's proprietary cellular discovery models have enabled researchers to investigate molecular pathways and chemical compounds in ways that could significantly impact understanding of cancer progression.

NeoGenomics Launches c-MET Companion Diagnostic for Advanced Non-Small Cell Lung Cancer Treatment

Targeted TherapyDrug ApprovalOncologyPrecision Medicine
  • NeoGenomics has commercially launched c-MET CDx for NSCLC, a companion diagnostic assay that detects c-Met protein overexpression in advanced non-small cell lung cancer patients with a 48-hour turnaround time.
  • The diagnostic test supports patient selection for newly FDA-approved targeted therapy EMRELIS™ (telisotuzumab vedotin-tllv), offering a precision medicine approach for a biomarker observed in up to 50% of advanced NSCLC patients.
  • This validated companion diagnostic complements NeoGenomics' broader PanTracer™ portfolio, enhancing comprehensive biomarker profiling capabilities for lung cancer treatment decisions.

NIH-Funded Teams Develop Precision Gene Delivery Systems for Neural Cells

Precision MedicineAI
  • Research teams funded by the NIH have created a versatile toolkit of gene delivery systems that can target specific neural cell types in the human brain and spinal cord with unprecedented precision.
  • The new delivery platform uses modified adeno-associated viruses (AAVs) to transport genetic material into targeted cells, potentially transforming how scientists study neural circuits without requiring genetically modified animals.
  • This breakthrough could accelerate the development of precise gene therapies for neurological disorders like ALS, Alzheimer's, and Parkinson's disease by targeting only affected cells rather than merely treating symptoms.

AI Tools Show Promise in Improving HER2 Breast Cancer Classification and Treatment Eligibility

AIPrecision MedicineOncology
  • A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.
  • The Digital PATH Project, involving 31 partners including pharmaceutical companies and academic centers, validated AI diagnostic technologies using 1,100 breast cancer tissue samples to assess consistency in HER2 expression identification.
  • AI tools particularly enhanced detection of HER2-low and HER2-ultralow expression levels, reducing misclassification by 24.4% and potentially expanding treatment eligibility for antibody-drug conjugates to patients previously classified as HER2-negative.

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Active, Not RecruitingPhase 3
AstraZeneca
Posted 7/24/2020

Patient-Derived Organoids and CRISPR Technology Transform Cancer Research and Precision Medicine

Precision Medicine
  • Patient-derived organoids (PDOs) have emerged as a transformative platform in cancer research, providing three-dimensional cell culture systems that retain the genetic variability and phenotypic diversity of primary tumors while enabling more accurate modeling of the tumor microenvironment compared to traditional 2D cultures.
  • CRISPR screening technology integrated with PDOs offers unprecedented capabilities for identifying genetic vulnerabilities in cancer cells, revealing drug resistance mechanisms, and discovering novel therapeutic targets through systematic gene editing and functional genomics approaches.
  • The combination of PDOs and CRISPR screening has demonstrated significant potential in advancing precision oncology by enabling patient-specific drug screening, identifying biomarkers for immunotherapy response, and developing personalized treatment strategies that could improve outcomes for cancer patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.